Kloepfel MagazinKloepfel Magazin
    Top Article

    Kloepfel Group awarded “Best Consultants” for the eighth year in a row

    20. March 2023

    Technical procurement

    20. March 2023

    Technical sourcing: Win-win for customers and suppliers instead of price squeezers

    20. March 2023
    Facebook Twitter Instagram
    • Kloepfel Group
    • Kloepfel Consulting
    • Kloepfel Karriere
    LinkedIn Twitter Facebook Instagram YouTube
    Kloepfel MagazinKloepfel Magazin
    • START
    • NEWS
      • HWWI
      • INTERVIEWS
      • CAREER
      • KLOEPFEL GROUP
      • WHITEPAPER
      • SURVEY
      • INDUSTRY NEWS
        • ENGINEERING
        • LOGISTICS
        • SUPPLY CHAIN
    • NEWSLETTER
    • CONTACT
      • IMPRINT
      • PRIVACY POLICY
    Kloepfel MagazinKloepfel Magazin
    Home»Industry News»Supply Chain»Pharmaceutical supply chains: EU advises on production sites in Europe
    Supply Chain

    Pharmaceutical supply chains: EU advises on production sites in Europe

    By Kloepfel1. May 2020Updated:19. May 20202 Mins Read
    LinkedIn Facebook WhatsApp Email
    Share
    LinkedIn Facebook Twitter WhatsApp Email

    Corona-Crisis inhibits supply from Asia

    EU health ministers held a video conference on Tuesday to discuss how to ensure the European supply of medicines. The reason for this was delivery shortfalls and delays of active ingredients and preparations from Asia.

    Cause for shortages often abroad

    An interview with Stefan Kluge in the ARD magazine “Plusminus” shows how serious the situation is. The director of intensive care medicine at the University Medical Center Hamburg said last week: “There are already hospitals in Germany that no longer have Propofol. Without Propofol, patients cannot be put under anesthesia – it is necessary, for example, for the ventilation of Covid-19 infected patients. The shortage is not only caused by increased demand: Problems at foreign production sites or long and confusing supply chains are frequent causes.

    Reduction of dependence on China and Co.

    Now the EU wants to reduce its dependence on production from foreign countries. Experience from the current pandemic would show that joint political efforts to expand pharmaceutical production at national level need to be stepped up to ensure independent and crisis-proof supply to the European population. All stakeholders (public authorities, NGOs, industry, marketing authorisation holders, wholesalers, pharmacies) should be involved at national and European level to take countermeasures.

    80 percent of all active ingredients from third countries

    This will be a non-inconsiderable challenge: 80 percent of all active ingredients in European medicines are sourced from third countries such as India, China and Taiwan. The reason for this is often the lower patent protection in these countries, so that generics can be produced and marketed in Europe before the patents expire in the EU area. Accordingly, production has been greatly expanded, and many preliminary stages are no longer produced in Europe. These are structures that have grown globally over decades.

    Source: www.kloepfel-consulting.com

    Share. LinkedIn Facebook Twitter WhatsApp Email

    Related Posts

    Stellantis invests $155 million in McEwen Copper

    20. March 2023

    Significantly fewer companies planning price increases

    20. March 2023

    BMW buys aluminum from sustainable production

    20. March 2023

    Stellantis buys nickel sulfate from Terrafame

    13. February 2023

    “Collaboration in the Supply Chain”

    13. February 2023

    Producer prices up 21.6 percent year-on-year in December

    13. February 2023

    Comments are closed.

    Top Artikel

    Kloepfel Group awarded “Best Consultants” for the eighth year in a row

    By Kloepfel20. March 2023

    As part of a representative survey conducted by the independent business magazine brand eins and…

    Technical procurement

    20. March 2023

    Technical sourcing: Win-win for customers and suppliers instead of price squeezers

    20. March 2023

    In purchasing lies the profit

    20. March 2023

    Dangers from cyber attacks

    20. March 2023
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • LinkedIn
    About us
    About us

    Das Magazin für den effektiveren Einkauf!

    Kloepfel Consulting GmbH
    Pempelforter Strsse 50
    40211 Düsseldorf

    Telefon: +49 211 941 984 33
    E-Mail: info@kloepfel-consulting.com

    New Article

    Kloepfel Group awarded “Best Consultants” for the eighth year in a row

    20. March 2023

    Technical procurement

    20. March 2023

    Technical sourcing: Win-win for customers and suppliers instead of price squeezers

    20. March 2023
    © 2023 Kloepfel Consulting GmbH All rights reserved
    • Home
    • News
    • Contact
    • Imprint
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.